Market Overview

Aurinia Pharmaceuticals Recognizes World Lupus DayTM with Activities Focused on Raising Awareness of Lupus Nephritis


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP), a clinical stage
biopharmaceutical company focused on the global immunology market, today
announced its support for World Lupus DayTM with activities
focused on raising awareness of lupus nephritis (LN). In honor of the
day, Aurinia is collaborating with The
, a digital health community created to empower and
connect people facing health challenges and disabilities. The
collaboration will raise awareness of lupus nephritis, a serious
comorbidity associated with Systemic Lupus Erythematosus (SLE).

SLE is a chronic, complex and often disabling disorder affecting an
estimated 5 million people around the world, which are mostly women,
according to the World Lupus Federation. LN is a debilitating and costly
inflammation of the kidney that affects up to 50% of all SLE patients.
If poorly controlled, LN can lead to end-stage renal disease (ESRD), a
severe and potentially life-threatening condition that requires dialysis
or a kidney transplant.

To raise awareness of LN, Aurinia is connecting patient advocate,
Gabrielle Davis, with The Mighty on World Lupus Day to share her
story "When
Marriage Works Harder Because Your Kidneys Don't."
Bringing to life
the daily struggle of living with lupus and LN, Davis' story, which
includes links to patient resources, can be seen on The Mighty
and its social channels throughout the month of May.

"Aurinia is proud to join the global lupus community to recognize and
support this important initiative. We wanted to share Gabrielle's
inspiring story of the challenges of living with lupus nephritis on
World Lupus Day to help shine a light on the nearly five million people
worldwide who suffer from SLE," said Richard M. Glickman, Chief
Executive Officer and Chairman of the Board of Aurinia. "It is important
for us to celebrate her determination to live her best life as well as
show the courage and dedication patients living with LN demonstrate each

In addition to Davis' story, Aurinia is supporting a dedicated homepage
within The Mighty with links to resources and stories for the
Lupus community.

The Mighty collaboration follows the recent launch of ALL
an educational website Aurinia developed for people living with
LN, which will add a new interactive tool in recognition of World Lupus
Day and Lupus Awareness Month. The tool will provide an opportunity for
those with LN to build and share their own personal story. The site also
features information about LN, downloadable resources, helpful links,
and personal stories and insights shared by people affected by the
disease. To learn more about LN, visit ALL IN at

About World Lupus Day

Lupus Day
is sponsored by the World Lupus Federation, a coalition of
lupus patient organizations from around the world, united to improve the
quality of life for people affected by lupus. Through coordinated
efforts of its global affiliates, the World Lupus Federation works to
create greater awareness and understanding of lupus, provide education
and services to people living with the disease, and advocate on their
behalf. Learn more at

World Lupus Day serves to call attention to the impact that lupus has on
people around the world. The annual observance focuses on the need for
improved patient healthcare services, increased research into the causes
of and cure for lupus, earlier diagnosis and treatment of lupus, and
better epidemiological data on lupus globally. World Lupus Day serves to
rally lupus organizations and people affected by the disease around the
world for a common purpose of bringing greater attention and resources
to efforts to end the suffering caused by this disabling and potentially
fatal autoimmune disease

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company
focused on developing and commercializing therapies to treat targeted
patient populations that are suffering from serious diseases with a high
unmet medical need. The company is currently developing voclosporin,
an investigational drug, for the potential treatment of lupus nephritis,
focal segmental glomerulosclerosis, and Dry Eye Syndrome. The company is
headquartered in Victoria, British Columbia and focuses its development
efforts globally. For further information, see our website at

We seek safe harbor.

View Comments and Join the Discussion!